Delaware rarely reverses itself. When it does, the reversal usually signals a shift not in doctrine but in temperament — a sense that the court is tired of a line of cases and wants it closed. Moelis & Co. v. West Palm Beach Firefighters’ Pension Fund is one of those cases. In March 2026, the Delaware Supreme Court reversed the Court of Chancery’s holding that a raft of stockholder-agreement provisions at Moelis were facially invalid under Delaware law. It did so on the narrowest possible ground — time-bar — but the signal runs deeper. Stockholder agreements of the kind almost every venture- and PE-backed company uses have, at least for now, survived the reckoning they looked like they were heading into.
If you have ever signed a founder-side stockholders’ agreement and wondered which of those blocking rights, consent rights, and board-composition covenants would actually hold up in litigation, Moelis is the case you should know. This post is for the lawyers who draft these agreements, the founders who sign them, and the limited partners who fund the PE sponsors that negotiate them.
What the Court of Chancery held, and why everyone panicked
The underlying Moelis stockholder agreement was a pretty standard PE-backed financing document. It contained what I will call the usual trio — a set of consent rights giving the principal stockholder veto power over specified corporate actions; board composition covenants committing the company to nominate the stockholder’s designees; and a handful of procedural commitments, including committee-composition and chair-selection rights.
Vice Chancellor Laster’s 2024 opinion held that many of these provisions violated DGCL § 141(a), which vests the management of the corporation in the board of directors. The theory was that the stockholder agreement was effectively stripping the board of its statutory authority and assigning it to a contract with a single large holder. Some provisions were held facially invalid; others were salvaged if they appeared in the charter; others were held inconsistent with fiduciary duty.
The decision landed like a rock in a pond. Venture funds, PE sponsors, sovereign wealth funds — anyone with a large minority position in a Delaware private company — had to look at their stockholder agreements and ask which clauses were still enforceable. Some pointed to the 2025 DGCL amendments that codified stockholder-agreement validity (the so-called Moelis patch), but those amendments had their own uncertainties, including retroactive effect. And then came the appeal.
The Supreme Court’s move: decide the narrow question, reserve the big one
The Supreme Court reversed, but not on the merits. The plaintiff pension fund had filed its complaint more than three years after the stockholder agreement was executed. Delaware’s default three-year statute of limitations for contract claims applied. There were no laches-tolling arguments strong enough to extend the window. The claims were time-barred.
The court’s opinion is a model of tactical restraint. It walks through the statute of limitations analysis carefully, holds that the plaintiff’s “continuing injury” theory fails because each consent right was a discrete contractual obligation that became enforceable on execution, and disposes of the case on that basis. It does not reach the merits of § 141(a). It does not endorse the Chancery reasoning, but it does not overrule it either. The doctrinal question is left open for another day.
Read strictly, then, the Supreme Court’s holding is simply that the plaintiff sued too late. Read for its signals, it is quite a bit more. The court had the opportunity to reach the merits and chose not to. That choice, combined with the 2025 DGCL amendments and the general tone of recent Delaware decisions, strongly suggests that the Chancery opinion is not going to set the shape of Delaware stockholder-agreement law.
The statute of limitations analysis actually matters
One piece of the opinion deserves its own attention. The Supreme Court held that the three-year clock started running on execution of the stockholder agreement, not on each exercise of the consent rights. That is important. It means that a stockholder who wants to challenge a governance provision in a stockholder agreement has three years from signing to bring the claim, full stop. After that window, the provisions are effectively grandfathered into whatever validity they have — not because they have been validated, but because no one can sue to invalidate them anymore.
The practical implication is immediate. Stockholder agreements executed more than three years ago are, as a practical matter, outside the reach of facial challenges. Stockholder agreements executed within the last three years are not. If you are a company counsel holding an agreement from 2022 or 2023 that contains provisions of the kind Vice Chancellor Laster flagged, you are in the litigation zone. If your agreement is from 2018, you probably are not.
What the opinion does for deal practice
Three things to take from the case, in descending order of confidence.
First, the Moelis patch in the 2025 DGCL is the primary source of validity for most of the provisions that were challenged. The patch expressly authorizes stockholder-agreement provisions that commit the corporation to stockholder-designated directors, require the company to submit particular actions to stockholder approval, and similar structural commitments. Lawyers drafting new agreements in 2026 and beyond should cite the patch, not litigate around the Chancery opinion. The patch is doing the work.
Second, the old habit of putting governance provisions in the charter rather than in the stockholder agreement is no longer strictly necessary, but it remains the safer practice where the provisions are meant to bind for the long term. Charter-level provisions get the full force of § 242 amendments behind them and are less vulnerable to doctrinal shifts. For PE sponsors contemplating a ten-year hold, a charter parked provision is still the right drafting move.
Third, the opinion leaves open a theoretical future attack on stockholder agreements on fiduciary-duty grounds — that is, even a facially valid provision could be unenforceable in a particular transaction if it operates to allow a director to breach the duty of loyalty. That door is still open. But it is a narrow door, requiring proof of actual breach rather than theoretical invalidity, and it is not going to come up in most deal postures.
What founders should take from this
If you are a founder who has signed — or is about to sign — a PE-backed stockholders’ agreement with consent rights, board-composition covenants, or similar governance provisions, the current state of the law is that those provisions are enforceable. You can rely on the 2025 DGCL amendments. You can rely on the Moelis Supreme Court’s tactical restraint. You cannot rely on a future merits ruling to invalidate them.
What you can and should do is the same thing you should have been doing before Moelis — read the provisions, understand what you are signing, negotiate the scope of the consent rights, and keep sunset clauses where possible. We have written more on that negotiating dynamic in our founder commentary on PE stockholders’ agreements, which covers the specific clauses founders should fight for and the ones that are usually reasonable trades.
The broader signal
Put together, Moelis and Rutledge (which I wrote about here) tell the same story from different angles. Delaware is not interested in a doctrinal blow-up that would disrupt the stockholder-agreement architecture that every funded private company depends on. The Supreme Court is using whatever tools it has — statutory interpretation, procedural doctrine, tactical restraint — to keep the private-company governance system stable while the General Assembly continues to update the DGCL.
For practitioners, that means fewer landmark Chancery opinions driving common-law change, more legislative activity, and more reliance on the text of the DGCL as it stands from year to year. For founders and deal lawyers, it means a more predictable legal environment than the last two years suggested we were heading into. That is, on balance, a good thing.
If you are working through a stockholder-agreement issue right now — a new financing with complicated consent rights, a challenge to an existing agreement, a question about how the 2025 DGCL amendments interact with an older document — feel free to reach out to my firm manager, Magda, at Magda@montague.law, or fill out our contact form. Mention you read this post.
— John
